Key facts
- OsciFlex’s last known valuation is $2.0M (Jan 2022).
- It has raised $5.6M; the latest was Later Stage VC in Jan 2025.
- Notable investors include US National Science Foundation, Ben Franklin Technology Partners of Southeastern Pennsylvania, John Martinson, Martinson Ventures, Penn Center for Innovation — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for OsciFlex
- ·The full record, as it builds
Funding rounds
No funding rounds for OsciFlex are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OsciFlex
Developer of pneumatic limb compression medical devices designed for the prevention of venous thromboembolic conditions in immobile patients. The company's device stimulates calf muscle contraction through the muscle stretch reflex, creates valve sinus recirculatory flow, and reduces the use of expensive and risky anti-coagulation pharmaceuticals, enabling doctors and hospital care providers to reduce clot formation risk and support thrombosis prevention without reliance on pharmacological anticoagulation.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2017
- Employees
- 2
- Website
- osciflex.com/
- Ownership
- Privately Held (backing)
OsciFlex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OsciFlex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OsciFlex in its N-PORT filings yet. We sweep new filings monthly.